# Bio-Conscious Technologies Inc.

> Predictive metabolic AI that reads continuous glucose monitoring (CGM) data to predict, prioritize, and prevent metabolic disease. Headquartered in Vancouver, Canada. Founded 2016.

## About
Bio-Conscious builds Endobits, a clinical decision-support platform (not a medical device) that reads the shape of glucose curves to forecast glucose up to 12 hours ahead, cluster patients into distinct glucotypes, and turn continuous glucose data into clinical action.

## Key facts
- Product: Endobits — CGM intelligence, forecasting and risk stratification for clinics
- Forecast horizon: up to 12 hours ahead
- Sensor partners: Dexcom, Abbott (FreeStyle Libre), Senseonics (Eversense, implantable)
- Approach: models glucose curve shape and variability, not just averages; glucotype phenotyping
- Regulatory: HIPAA-compliant; decision-support, not a medical device; designed for Medicare RPM/CCM reimbursement
- Validation: research presented at ADA Scientific Sessions (78th–84th); awarded PacifiCan RAII funding
- Beyond diabetes: glucose metabolism is linked to all 12 hallmarks of aging (healthspan)
- Contact: contact@bioconscious.tech

## Links
- Website: https://bioconscious.tech/
- LinkedIn: https://www.linkedin.com/company/bioconscious/
- Privacy Policy: https://www.endobits.com/privacy
- Terms of Service: https://www.endobits.com/terms